Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

• Status: NOT_YET_RECRUITING
• Trial end date: 2028-05-31

Summary

This trial is a single-arm exploratory phase II clinical study initiated by the investigator.

Subjects who met the research criteria were screened and enrolled to receive the treatment regimen of disitamab vedotin combined with lenvatinib and PD-1 inhibitor. During the treatment process, the researchers closely followed up, strictly evaluated the efficacy, assessed the efficacy and safety of the subjects after receiving the combined treatment, evaluated the subjects until progression occurred, and observed their objective response rate, progression-free survival, overall survival, disease control rate, duration of response, and safety evaluation.

• Phase: PHASE2

Details

• Lead Sponsor: Peking Union Medical College Hospital
• Treatments: camrelizumab; disitamab vedotin; lenvatinib; pembrolizumab; toripalimab